Literature DB >> 21844806

Gastrointestinal infections and the development of irritable bowel syndrome.

Herbert L Dupont1.   

Abstract

PURPOSE OF REVIEW: Approximately 10% of the millions of persons with functional gastrointestinal disorders (FGDs) including irritable bowel syndrome (IBS) had their illness onset following an acute bout of infectious diarrhea and are referred to as having postinfectious (PI) FGD or PI-IBS. Recent studies have helped to identify the pathogenesis and natural history of these disorders. RECENT
FINDINGS: Groups of patients with acute diarrhea or dysentery (passage of grossly bloody stools) are being followed for development of PI-IBS. Persistent mucosal inflammation, air trapping in the gut, and alteration of intestinal motility contribute to the disease symptoms in genetically susceptible persons. The prognosis of postinfectious forms of IBS is more favorable compared with people with idiopathic forms of the disorder.
SUMMARY: With full characterization of postdiarrhea forms of FGDs, we should be able to define the mechanisms of disease early in the course of chronic illness and to better understand the more common idiopathic forms of the disease. We are likely to identify specific alteration of gut pathophysiology in postinfectious FGDs and to then classify them not as a poorly characterized group of functional disorders but as specific gastrointestinal disorders.

Entities:  

Mesh:

Year:  2011        PMID: 21844806     DOI: 10.1097/QCO.0b013e32834a962d

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  9 in total

Review 1.  Enterotoxigenic Escherichia coli Infections.

Authors:  James M Fleckenstein; F Matthew Kuhlmann
Journal:  Curr Infect Dis Rep       Date:  2019-03-04       Impact factor: 3.725

Review 2.  Diversity, stability and resilience of the human gut microbiota.

Authors:  Catherine A Lozupone; Jesse I Stombaugh; Jeffrey I Gordon; Janet K Jansson; Rob Knight
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

3.  Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.

Authors:  Adam Deising; Ramiro L Gutierrez; Chad K Porter; Mark S Riddle
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-03

Review 4.  Chronic functional bowel syndrome enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2014-03-04       Impact factor: 3.996

5.  2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea.

Authors:  Andi L Shane; Rajal K Mody; John A Crump; Phillip I Tarr; Theodore S Steiner; Karen Kotloff; Joanne M Langley; Christine Wanke; Cirle Alcantara Warren; Allen C Cheng; Joseph Cantey; Larry K Pickering
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

Review 6.  Gut Dysbiosis and Clostridioides difficile Infection in Neonates and Adults.

Authors:  Iulia-Magdalena Vasilescu; Mariana-Carmen Chifiriuc; Gratiela Gradisteanu Pircalabioru; Roxana Filip; Alexandra Bolocan; Veronica Lazăr; Lia-Mara Diţu; Coralia Bleotu
Journal:  Front Microbiol       Date:  2022-01-20       Impact factor: 5.640

7.  Systematic analysis of funding awarded for norovirus research to institutions in the United Kingdom, 1997-2010.

Authors:  Michael G Head; Joseph R Fitchett; Rifat Atun
Journal:  J R Soc Med       Date:  2013-11-21       Impact factor: 5.344

8.  Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome.

Authors:  Charles Darkoh; Latoya Comer; Getie Zewdie; Stephen Harold; Ned Snyder; Herbert L Dupont
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

9.  Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy.

Authors:  Emma Torbicki; Justin Oh; Sharmistha Mishra; Andrea V Page; Andrea K Boggild
Journal:  Trop Dis Travel Med Vaccines       Date:  2015-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.